Identification and Analysis of Differentially Expressed Genes in Human Saphenous Vein Endothelial Cells Overexpressing Domain-Containing mTOR-Interacting Protein (DEPTOR) by RNA-Seq

ABCE 1 Wenjun Wang*
BD 2 Yiying Li*
BCDF 1 Qun Wang
CDE 1 Yuanping Cao
BDEF 1 Fudong Wang
ABDEFG 1 Wan Li

*Wenjun Wang and Yiying Li contributed equally to the work

Corresponding Author: Wan Li, e-mail: WanLi6446@163.com

Background: Autologous saphenous vein is the most common choice for coronary artery bypass grafting. This study was conducted to identify and characterize differentially expressed genes (DEGs) induced by overexpressing DEPTOR in human saphenous vein endothelial cells (hsVECs) that might play roles in restenosis.

Material/Methods: hsVECs isolated from the saphenous veins were transfected with DEPTOR overexpression vector and analyzed for mTOR expression. RNA was prepared from the cells and sequenced using high-throughput sequencing technology (RNA-Seq). The DEGs were analyzed based on enrichment scores in GO terms and KEGG pathways.

Results: The cells had typical hsVEC morphology and characteristics based on the HE staining and immunohistochemical and immunofluorescence assays. The expression of mTOR increased, and 102 genes were upregulated, and 409 genes were downregulated after DEPTOR overexpression. KEGG analysis showed that the DEGs were mainly enriched in 20 signal pathways, such as Focal adhesion and ECM-receptor interaction pathways. The DEGs were enriched in GO terms such as integrin binding and glycosaminoglycan binding. For cellular components, GO analysis revealed that the DEGs were enriched in main axon, plasma membrane part, cell junction, and proteinaceous extracellular matrix. DEGs included many cytokines, such as bone morphogenetic protein-7, interleukin-8, interleukin-1β, and inhibin, which have important effects on vascular growth and inflammation.

Conclusions: The overexpression of DEPTOR in hsVECs results in DEGs that are involved in cell proliferation and differentiation, intercellular junction, and extracellular matrix receptor. These findings may provide valuable molecular information for improving venous permeability through manipulation of DEPTOR and related mTOR pathways.

MeSH Keywords: Coronary Artery Bypass • Coronary Restenosis • Gene Expression

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/915442

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
**Background**

Coronary artery bypass grafting (CABG) is a typical application of arterial bypass grafting, and is mainly used to treat ischemic heart diseases [1]. Autologous saphenous vein is the most common choice for CABG [2]. However, restenosis rates at 1 year and 10 years after CABG have been reported to be 15% and 50%, respectively [3]. Rapamycin is an inhibitor of mammalian target of rapamycin (mTOR). It inhibits cell proliferation and is used to prevent restenosis[4–6]. mTOR has 2 structurally and functionally different complexes – mTORC1 and mTORC2 – and the latter is relatively insensitive to rapamycin [7,8]. DEPTOR (domain-containing mTOR-interacting protein) is another common component of mTORC1 and mTORC2. DEPTOR also directly interacts with mTOR. It has been reported that the overexpression of DEPTOR downregulates the activity of mTORC1 and mTORC2 [9,10]. In addition, studies have reported that DEPTOR regulates the synthesis of fat [11]. Therefore, DEPTOR has great value in improving blood flow in the human saphenous vein. To better explore the molecular roles of DEPTOR, high-throughput sequencing technique (RNA-Seq) was used to identify and characterize differentially expressed genes (DEGs) induced by DEPTOR. These findings may provide valuable molecular information and clues for improving venous permeability through manipulation of DEPTOR and related mTOR pathways.

**Material and Methods**

**Tissues and reagents**

Human saphenous veins abandoned in CABG were obtained from the Surgery Department of the First Affiliated Hospital of Nanchang University. pcDNA3.1 was used to construct a DEPTOR expression vector pcDNA-DEPTOR. DMEM/F-12 (1: 1) (cat. no. 1861453) and Opti-MEM (cat. no. 331985-062) were obtained from GIBICO, USA. Lipofectamine 3000 (cat. no. 1882752) was purchased from Invitrogen, USA. Human bFGF (cat. no. L10402031) and human EGF (cat. no. N10504031) were obtained from Cyagen, USA. Mouse monoclonal antibody against GAPDH (1/2000, cat. no. TA-08), goat anti-mouse IgG (1/2000, cat. no. ZB-2305) and anti-rabbit IgG (1/2000, cat. no. ZB-2301) were purchased from Zsbio, Beijing, China. Rabbit polyclonal antibody against mTOR (1/2000, cat. no. ab2732) was purchased from Abcam, USA. Rabbit antibodies against CD31 (1/2000, cat. no. BA2966), CD34 (1/2000, cat. no. PB0031) and vWF (1/2000, cat. no. bs-20428R) were purchased from BOSTER, Beijing, China. Conjugated goat anti-rabbit IgG Cy3 (1/2000, cat. no. CW0159S) was purchased from CWBIO, Wuhan, China. Rabbit anti-factor VII (1/1000, cat. no. bs-2974R) and HRP labeled anti-rabbit IgG (1/2000, cat. no. SV0002) were obtained from Bioss, Beijing, China.

**Cell isolation and culture**

hsVECs were isolated from the abandoned saphenous veins as described previously [12]. Six segments of 1 cm end segments of saphenous vein were taken from each of 3 patients and used together in the study. Briefly, a syringe with a lavage needle was inserted into one end of the vein. The venous cavity was washed repeatedly with PBS. Then, the washed vein was injected with collagenase II (1 g/L) and incubated in a CO₂ incubator at 37°C for 15 min. The digest was collected and centrifuged at 4°C for 5 min. The cells were suspended and cultured in DMEM/F12 medium with 20% FBS, streptomycin and penicillin mixture (cat. no. 1400, Solarbio, USA), hEGF(10μg/L), 1% insulin-transferrin-selenium (ITS) (cat. no. 41400-045, Gibco, USA), and hbFGF (3ng/mL) in a 5% CO₂ incubator at 37°C.

**HE staining**

The tissue samples were fixed with formalin, embedded in paraffin, and sectioned into 4-μm-thick slices. The sections were baked, dewaxed, rehydrated, and stained with hematoxylin solution for 3 min. After differentiation with hydrochloric acid ethanol solution for 15 s, the slides were stained again for 15 s with eosin. The slides were viewed under a microscope after being sealed with neutral resin.

**Immunohistochemistry**

The cells were incubated with antibodies against factor VIII for 2 h at room temperature followed by incubation with appropriate secondary antibodies for 1 h, and mounted with Prolong antifade reagent (Invitrogen). Diaminobenzidine (DAB) and hematoxylin chromogen (Dako, Glostrup, Denmark) method was used. The sections were subsequently examined by light microscopy.

**Immunofluorescence**

The cells were immobilized with 4% paraformaldehyde for 15 min, cleared with 0.5% Triton X-100 at room temperature for 20 min, and blocked with 5% BSA at 37°C for 30 min. The cells were stained with antibodies against CD31, CD34, or vWF at 4°C overnight. Cy3 antibody was added drop-wise to cells and incubated at 37°C for 30 min. DAPI was used to stain the nuclei, and the slides were viewed under a fluorescence microscope. The red fluorescence was from the proteins of interest, while the blue fluorescence was from the nucleus.

**Transfection**

hsVECs were grown to 90% confluence and transfected with pcDNA- DEPTOR using Lipofectamine 3000 according to the manufacturer’s instructions. pcDNA 3.1 was used as negative control.
control. Transfected cells were cultured in DMEM/F12 medium with 20% FBS for 24 h and harvested for transfection efficiency assays.

**Construction of Illumina sequencing library**

Total RNA was isolated from the cells using the TRIzol reagent (Invitrogen). The concentration and purity of the RNA were detected using Nanodrop 2000 and the RNA integrity was checked using agarose gel electrophoresis. We used the Ribo-Zero Magnetic Kit and RNase R (EpiCenter, USA) to remove rRNA and linear RNA. The purified RNA was used to construct a paired-end library using the TruSeq™ Stranded Total RNA Library Prep Kit (Illumina, USA) for sequencing on the Hiseq4000 platform according to the supplier’s instructions.

**Sequence analysis**

SepPrep and Sickkle software were used to test the quality of the reads. The reads were then aligned with the human reference genome [13] using Bowtie to generate the gene lists. Sequences from cells transfected with pcDNA-DEPTOR or transfected with pcDNA 3.1 were compared to generate differentially expressed genes (DEGs).

**Enrichment analysis of DEGs**

Goatools was used to enrich GO function (molecular function, cell components, biological processes) [14–16] and KOBAS was used to enrich KEGG Pway and annotate KEGG functions [17,18].

**Statistical analysis**

Data were expressed as means ±s.d. and were analyzed using the statistical analysis software SPSS 19.0. Student’s t-test was performed to compare the difference between groups and P<0.05 were considered as statistically significant.

**Results**

**Characterization of primary hsVEC culture**

The morphology of primary hsVEC culture is shown in Figure 1A. HE staining and immunohistochemical staining of endothelial factor VIII (Figure 1B, 1C) showed that the culture had typical features of hsVECs. In addition, endothelial markers were detected in the cytoplasm (CD31), nuclei (CD34), and the junctions between the cells (vWF) in the cultured cells (Figure 2), further demonstrating that they are hsVECs.

**DEPTOR increased after transfection**

When the cells were transfected with pcDNA-DEPTOR, the mRNA and protein levels of DETOR were significantly upregulated (p<0.05, Figure 3).

---

**Figure 1.** Culture and characterization of hsVEC. (A) Morphology of primary hsVEC culture. (B, C). HE staining and immunohistochemical staining of endothelial factor VIII.

**Indexed in:** [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

---

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Figure 2. Immunofluorescence assays of endothelial markers CD31, CD34, and vWF in cultured hsVECs.

Figure 3. Expression of mTOR mRNA and protein in hsVECs transfected with pcDNA-DEPTOR. (A) mRNA level. (B) Left panel: representative Western blots, right panel: relative protein levels. * Denotes significantly difference vs. control.
Differentially expressed genes following DEPTOR overexpression

To obtain the gene expression profiles following DEPTOR overexpression, RNA samples were isolated from hsVECs transfected with and without DEPTOR expression cassette. The samples were sequenced on an Illumina HiSeq 4000 platform. Quality control on the raw reads was performed using SepPrep and Sickloler. Analysis showed that there were 102 upregulated and 409 downregulated genes in DEPTOR-transfected cells.

Figure 4. MA-plots showing fold change in expression generated by comparing DEPTOR overexpression vs. empty vector. The plots were obtained using DEGseq package, where M (Y-axis) represents the intensity ratio log2 (fold change), and A (X-axis) represents the average intensity.

Figure 5. KEGG pathway analysis of DEGs identified in hsVECs. The ordinate is the KEGG Pathway entry; the abscissa is the ratio of the number of differentially enriched genes to the number of genes annotated on the pathway. The size of the dot in the graph represents the number of differentially enriched genes and the number of genes annotated on the pathway. The color represents the significance of the pathway P. The smaller the P value is, the more significant the enrichment is.
as compared with empty vector-transfected cells (Figure 4, Supplementary Table 1, [Supplementary/raw data available from the corresponding author on request]).

**KEGG pathway analysis of DEGs**

KEGG pathway analysis showed that the differentially expressed genes were mainly concentrated in 20 signaling pathways, such as Focal adhesion, ECM-receptor interaction, Cytokine-cytokine receptor interaction, and PI3K-Akt signaling pathway (Figure 5).

**GO analysis of DEGs**

GO enrichment analysis showed that in molecular functions, the DEGs were concentrated in integrin binding, glycosaminoglycan binding, RNA polymerase II regulatory region sequence-specific DNA binding, and extracellular matrix structural constituent (Figure 6A). In biological process, enriched GO terms included cell differentiation, anatomical structure morphogenesis, and system development (Figure 6B). For cellular components, GO analysis revealed that differentially expressed genes were enriched in GO terms such as main axon, plasma membrane part, cell junction, and proteinaceous extracellular matrix (Figure 6C).

**Discussion**

CABG uses autologous veins to bridge arteries, and the vein segment actually acts as an artery after the operation, which is thus subjected to different hemodynamic conditions and increased partial pressure of oxygen after the surgery. In order to adapt to this change, the wall of the vein will gradually become thicker and harder and the diameter expands [19,20]. It has been reported that if the vein was grafted back to the venous environment 2 weeks after CABG, there are restorative changes in the vein [21]. In this dynamic and reversible process, the role of endothelial cells needs to be defined.

The main reason for the gradual hardening of the vein wall is the remodeling of matrix proteins [22]. These proteins are in the signal pathways identified in this study, such as Focal adhesion, Cell adhesion molecules, ECM-receptor interaction, Cytokine-cytokine receptor interaction, and PI3K-Akt signaling pathway. DEPTOR is a component of mTORC1 and mTORC2, and mTOR regulates cell proliferation mainly through downstream PI3K-Akt pathways [23]. In our work, these pathways were enriched with 19 DEGs; among them, 5 were upregulated and 14 were downregulated after DEPTOR overexpression. In addition, DEGs were identified in GO terms RNA polymerase II regulatory region sequence-specific DNA binding, suggesting that it has a regulatory role in gene expression. Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, and NF-kappa B signaling pathway are also significant signaling pathways that are associated with inflammatory response [24,25]. We found that 3 upregulated and 14 downregulated DEGs were enriched in the Cytokine-cytokine receptor interaction pathway; 1 upregulated and 5 downregulated DEGs were enriched in the TGF-beta signaling pathway; and 3 upregulated and 4 downregulated DEGs were enriched in the NF-kappa B signaling pathway. The Cytokine-cytokine receptor interaction and GF-beta signaling pathways had the same 4 DEGs: ENSG00000139269 (inhibin βE chain), ENSG00000101144 (bone morphogenetic protein 7), ENSG00000122641 (inhibin βA chain), and ENSG00000163083.

**Figure 6.** GO term analysis of DEGs identified in in hsVECs. (A) Molecular functions. (B) Biological process. (C) Cellular components.
Differentially expressed genes induced by overexpressing DEPTOR in hsVECs are involved in cell proliferation and differentiation, intercellular junction, and extracellular matrix receptor. These genes should be further explored for their biological roles and may provide molecular cues to improve venous permeability through manipulation of DEPTOR and related mTOR pathways.

Conflicts of interests
None.

Conclusions
Since more than 200 DEGs have been identified, these genes would provide candidates for functional analysis and lay a foundation for functional and molecular biological analysis.

References:

1. Hillis LD, Smith PK, Anderson JL et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011; 124: 2610–42
2. Bhasin M, Huang Z, Pradhan-Nabzky L et al. Temporal network based analysis of cell specific vein graft transcriptome defines key pathways and hub genes in implantation injury. PLoS One, 2012; 7: e39123
3. Head SJ, Borgermann J, Osnabrugge RL et al. Coronary artery bypass grafting: Part 2 – optimizing outcomes and future prospects. Eur Heart J, 2013; 34: 2873–86
4. Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation, 2001; 103: 192–95
5. Morice MC, Serruys PW, Sousa JE et al., RAVEL Study Group. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation, 2002; 110: 773–80
6. Hausleiter J, Kastrati A, Mehilli J et al., OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation, 2002; 110: 773–80
7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Annu Rev Genet, 2006; 40: 711–45
8. Hausleiter J, Kastrati A, Mehilli J et al., OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation, 2002; 110: 773–80
9. Hausleiter J, Kastrati A, Mehilli J et al., OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation, 2002; 110: 773–80
10. Hausleiter J, Kastrati A, Mehilli J et al., OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation, 2002; 110: 773–80
11. Hausleiter J, Kastrati A, Mehilli J et al., OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation, 2002; 110: 773–80
12. Li B, Liu N: [In vitro culture of human saphenous vein endothelial cells.] Chinese Journal of Cell Biology, 2005; 27: 474–76 [In Chinese]